l e t t e r s
Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality worldwide 1 . We performed a genetic association study in 15,256 cases and 47,936 controls, with replication of select top results (P < 5 × 10 −6 ) in 9,498 cases and 9,748 controls. In the combined meta-analysis, we identified 22 loci associated at genome-wide significance, including 13 new associations with COPD. Nine of these 13 loci have been associated with lung function in general population samples [2] [3] [4] [5] [6] [7] , while 4 (EEFSEC, DSP, MTCL1, and SFTPD) are new. We noted two loci shared with pulmonary fibrosis 8, 9 (FAM13A and DSP) but that had opposite risk alleles for COPD. None of our loci overlapped with genome-wide associations for asthma, although one locus has been implicated in joint susceptibility to asthma and obesity 10 . We also identified genetic correlation between COPD and asthma. Our findings highlight new loci associated with COPD, demonstrate the importance of specific loci associated with lung function to COPD, and identify potential regions of genetic overlap between COPD and other respiratory diseases.
COPD is characterized by persistent and progressive airflow limitation diagnosed by lung function testing 1 . Cigarette smoking is the major risk factor, but susceptibility is also influenced by genetics [11] [12] [13] . We established the International COPD Genetics Consortium (ICGC) to coordinate efforts to find susceptibility loci 14 . We defined cases on the basis of pre-bronchodilator evidence of moderate-to-severe airflow limitation by modified GOLD criteria 15 ; controls had normal spirometry measures, and all analyses were adjusted for age, sex, and cigarette smoking (pack-years and smoking status). We performed a two-stage genome-wide association study (GWAS) (Fig. 1) . In stage 1, we combined 26 cohorts (Supplementary Tables 1 and 2) comprising 63,192 individuals (15,256 COPD cases and 47,936 controls). We selected 79 loci with association P < 5 × 10 −6 and, in analysis stage 2, tested these loci in the UK BiLEVE data set (9,498 COPD cases and 9,748 controls) from the UK Biobank and performed an overall meta-analysis (Supplementary Table 3) .
We identified 13 genome-wide significant (P < 5 × 10 −8 ) associations in stage 1. Following the stage 2 analysis, an additional nine loci achieved genome-wide significance in the overall meta-analysis (Fig. 2 Fig. 3 and Supplementary Table 5 ) stage 1 cohorts did not identify unique association signals. Of the 22 genomewide significant loci described in our study, 9 have previously been described as genome-wide (or exome-wide) significant in studies Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis A full list of authors and affiliations appears at the end of the paper. Table 6 ) in general population GWAS of two measures of lung function (FEV 1 and FEV 1 /FVC) that are used in conjunction to diagnose COPD 2, [4] [5] [6] [7] 20, 21 . One locus near PID1 was previously associated with FEV 1 /FVC but had not replicated in the earlier studies 4, 6 . Four loci are newly described as genome-wide significant in association with either COPD or lung function: EEFSEC, DSP, MTCL1, and SFTPD (Fig. 3) .
To explore the potential functions and causal genes for our newly associated loci, in addition to using publicly available data sets and prioritization tools (Supplementary Table 7) , we examined a larger set of lung expression quantitative trait loci (eQTLs) in 1,038 subjects, including subjects with COPD 22 (Supplementary Table 8 ). As eQTLs are pervasive, we also attempted to determine whether our association signals colocalized 23 with an eQTL signal in lung tissue (Supplementary Table 9 ). We found strong evidence of colocalization (posterior probability > 0.8) for DSP, which encodes a major protein in desmosomes required for epidermal integrity 24 , and for MTCL1, which is important in epithelial-cell-specific microtubule stabilization 25, 26 and is expressed in respiratory epithelial cells 27 . Variants in strong linkage disequilibrium (LD) with our top MTCL1 variant rs647097 (NC_000018.9:g.8808464T>C) appear to have enhancer-associated histone marks in fetal lung fibroblasts 28, 29 . In contrast, we found no evidence of a strong eQTL signal or colocalization at our other two new loci. At 3q21, EEFSEC is a potential candidate gene, as it is a paralog of TUFM, a top blood and lung eQTL gene for the 16p11.2-IL27 COPD susceptibility locus 19 that was recently identified as part of a novel COPD-related pathway involving NLRX1 (refs. 30-32).
At 10q22, SFTPD (encoding pulmonary surfactant-associated protein D) is the most likely candidate gene, as it is highly expressed in pneumocytes 27 and Sftpd −/− mice develop pulmonary emphysema 33 . SFTPD has been explored as a COPD biomarker 34 , and, while rs721917 (NC_000010.10:g.81706324A>G) is not an eQTL, polymorphisms in SFTPD, including rs721917, may lead to decreased surfactant protein D levels 35 , although the association of SFTPD polymorphisms with COPD susceptibility has been inconsistent. Our analysis also led to additional insights into other previously described loci. We found evidence of COPD association and eQTL statistical colocalization in lung tissue (posterior probability > 0.8) for THSD4, HHIP, AGER, CHRNA3, and RARB (Supplementary Table 9 ). Additional data on eQTLs (Supplementary Table 8) , cohort-specific associations at each locus ( Supplementary Fig. 1a-v) , fine-mapping (Supplementary Table 10 and Supplementary Note), causal genes ( Supplementary  Tables 11 and 12) , and other supportive analysis for previously described and new loci can be found in the Supplementary Note.
We note that our top variant at DSP (rs2076295, NC_000006.11: g.7563232T>G) is also associated (P = 1.1 × 10 −19 ) with pulmonary fibrosis 8 . Recently, a resequencing study 36 at the DSP locus identified a second fibrosis-associated variant, rs2744371 (NC_000006.11: g.7554174A>C), with P fibrosis = 0.002 and P COPD = 0.04. We also note overlap at the FAM13A locus (top fibrosis SNP 8 , rs2609255 (NC_000004.11:g.89811195G>T); P fibrosis = 2.2 × 10 −11 , P COPD = 1.9 × 10 −7 ). We performed additional analysis to investigate genetic overlap using gwas-pw 37 (Supplementary Note). We confirmed overlap at the DSP and FAM13A loci with posterior probability > 0.99 and additionally discovered overlap near MAPT-KANSL1 (top fibrosis SNP 8 , rs1981997 (NC_000017.10:g.44056767G>A); P fibrosis = 8.87 × 10 −14 , P COPD = 4.5 × 10 −3 ) with posterior probability of 0.84. Although the MAPT-KANSL1 locus did not reach genome-wide significance in our study, we note its independent discovery in a l e t t e r s l e t t e r s genome-wide association analysis of extremes of lung function 7 . Notably, for all four of the variants (in DSP (two variants), FAM13A, and MAPT), the fibrosis risk allele is protective against development of COPD. Emphysema, a key component of COPD, and pulmonary fibrosis are both smoking-related lung diseases that have shared and distinct pathophysiology [38] [39] [40] , although genetic loci with opposing effects have not previously been described. Additional investigation of these loci as well as a more comprehensive assessment of genetic overlap of COPD and pulmonary fibrosis may lead to insight into both disorders.
Because our analysis relied on a spirometric definition of COPD alone, we did not specifically exclude other causes of airway obstruction such as asthma, which can overlap with COPD in adults 41 . To define COPD, we used pre-bronchodilator spirometry data, which were available across all cohorts, and we included at least moderately affected cases (FEV 1 < 80% predicted). We examined the genome-wide significant results in a subset of our largest cohorts with both pre-and post-bronchodilator data and densely imputed genotypes; overall, the effect sizes (mean difference = 0.001) and P values (mean log 10 P value difference = 0.18) were similar ( Supplementary  Figs. 4 and 5, and Supplementary Table 13 ). In addition, a recent GWAS of FEV 1 , FVC, and FEV 1 / FVC did not find substantial differences when subjects with asthma were included or excluded 7 . For the 79 variants tested in stage 2, we found no significant difference in the odds ratio for COPD association when including and excluding individuals with asthma ( Supplementary Fig. 6 ).
We examined the COPD associations of genome-wide significant loci for asthma (and loci for asthma-associated traits) from the NHGRI-EBI GWAS Catalog 42 (Supplementary Table 14) . We also compared our COPD association results to the GABRIEL asthma study 43 Table 15 ). None of the genome-wide significant loci for asthma and COPD overlapped. Further, no loci for asthma or COPD showed Bonferroniadjusted (for the number of lookups) significant association with the other disease, although several loci showed nominal (P < 0.05) significance. The 16p11.2 (CCDC101) locus has been described in joint susceptibility to asthma and obesity 10 . COPD susceptibility is strongly related to cigarette smoking. Two of our loci (15q25 and 19q13) have previously been associated with smoking behavior 44, 45 , although we found no additional evidence of overlap in genome-wide significant variants described in the NHGRI-EBI GWAS Catalog 42 and the Tobacco and Genetics Consortium GWAS 45 (Supplementary  Tables 16-18 ). We additionally evaluated overlap of our top 22 loci with loci for COPD comorbidities (Supplementary Table 19 ) and radiographic imaging features (Supplementary Table 20) . OR, odds ratio; CI, confidence interval. An asterisk indicates genome-wide significant loci in overall meta-analysis only.
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l e t t e r s
In contrast to the minimal overlap in genome-wide significant results observed with asthma and smoking, we discovered a significant overall genetic correlation of COPD with asthma (genetic correlation (r g ) = 0.38, P = 6.2 × 10 −5 ) using LD score regression in our European-ancestry subjects 46, 47 . We also assessed genetic correlation with population-based measures of lung function, pulmonary fibrosis, smoking behavior, and two common COPD comorbidities, coronary artery disease and osteoporosis. We identified significant correlation of COPD with lung function and two aspects of smoking behavior, but not with common COPD comorbidities or with pulmonary fibrosis (Fig. 4) . The lack of significant correlation of COPD with pulmonary fibrosis may indicate that our overlapping loci for COPD and pulmonary fibrosis are not representative of a broader disease correlation; alternatively, it could reflect limited sample size or a mix of positive and negative genetic correlations across the genome for the diseases. In potential support of this latter hypothesis, and in contrast to the loci we describe in this study, rare variants have recently been described in telomerase genes predisposing to both emphysema, a key feature of COPD, and pulmonary fibrosis 40, 48 . Our analysis of partitioned heritability identified enrichment of COPD genetic associations in fetal lung tissue (coefficient P = 3.5 × 10 −7 ); other bioinformatic analyses also support functional annotation of COPD associations to lung tissue or lung cell types (Supplementary Note).
Our study is, to our knowledge, the largest GWAS of COPD cases thus far and comprises over 60,000 subjects (including 15,256 COPD cases) in the stage 1 analysis. We chose to combine subjects of different ancestry, hypothesizing that shared COPD risk factors across ancestry groups would outweigh power loss due to heterogeneity. While methods have been developed that can more rigorously assess the degree of overlap between ancestry groups and provide additional power in this setting 49 , none of our non-European-ancestry cohorts were sufficiently sized or powered for these analyses. COPD is also a highly heterogeneous disease; whether a more precise phenotypic definition would result in greater power is not clear. We used a staged study design and examined overall meta-analysis P values to determine genome-wide significance. Thus, the nine loci (TET2, CFDP1, TGFB2, AGER, ARMC2, PID1, MTCL1, SFTPD, and CYP2A6) from our stage 1 analysis that only reached genome-wide significance in either the stage 2 UK BiLEVE analysis or the overall meta-analysis should be further replicated. However, six of these nine association signals are significant if we consider a Bonferroni correction (P < 6.3 × 10 −4 ) for the 79 variants tested in stage 2. Further, eight of these nine variants are more strongly associated in the overall meta-analysis than they are in stage 1; the exception is RARB, which has previously reported associations with both lung function 4 and airflow obstruction 21 (Table 1) . 
The majority of our significantly associated loci overlap with loci for lung function, strengthening the foundation for investigating the relationship between variability in lung function in the general population and risk of developing COPD. These loci are unlikely to reflect susceptibility for asthma or for cigarette smoking; however, our association results as a whole show evidence of shared heritability with asthma (supporting investigation into shared genetic etiologies for these diseases) and cigarette smoking behavior (despite adjustment for smoking in our statistical model). We identify functional annotation enrichment for fetal lung cells, supporting a role for early life events in future risk of COPD. Finally, we identify loci that overlap with pulmonary fibrosis, but with opposite risk alleles. Our study highlights the important contribution of genetic association studies to understanding COPD, not only by identifying new loci but also by illustrating relationships with other pulmonary traits and diseases.
MethODs
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. An asterisk indicates nominal (P < 0.05) significance, and a double asterisk indicates significance after Bonferroni correction for the number of pairwise comparisons. FEV 1 /FVC ratio and FEV 1 data were obtained from CHARGE/SpiroMeta 4 , asthma data were taken from the asthma GWAS by the GABRIEL Consortium 43 , pulmonary fibrosis (ILD) data were from Fingerlin et al. 8, 9 , BiLEVE smokers correspond to the subset of smokers in the UK BiLEVE study 7 , data on cigarettes per day, current versus former smoking status, age of smoking initiation, and ever versus never smoking status were from the Tobacco and Genetics Consortium 45 , coronary artery disease (CAD) data were from the CARDIoGRAM study 50 , height 51 and body mass index (BMI) 52 data were from the GIANT Consortium, and lumbar and femoral bone mineral density (BMD) data were from the Genetic Factors for Osteoporosis (GeFOS) Consortium 53 .
ONLINe MethODs
Study cohorts. We invited investigators from 22 studies with genome-wide association data and COPD case-control or general population samples with spirometry to participate in a genome-wide association meta-analysis. Additionally, we included four cohorts with Illumina HumanExome v1.2 and custom genotyping based primarily on prior top results from a previously published COPD GWAS 13 , using results exhibiting P < 1 × 10 −4 using PLINK '--clump' on COPDGene non-Hispanic whites to perform LD pruning (r 2 < 0.8), preferentially retaining both an imputed and genotyped top SNP at each locus. An additional group of variants was a candidate panel, based on results from a previous candidate gene analysis 54 , as well as variants identified in association with lung function (supplementing the existing content on the array, which included variants from previous GWAS), including the lead SNP and a 200-kb region around that SNP pruned for variants with P < 0.01 and r 2 < 0.8, and additional top ranked SNPs from COPDGene-specific analyses for lung function, bronchodilator responsiveness, and exacerbations and SNPs from candidate genes. The baseline characteristics of these 26 cohorts can be seen in Supplementary  Table 1 . Each cohort obtained approval from appropriate ethical/regulatory bodies; informed consent was obtained for all individuals. (Further cohortspecific methods can be found in the Supplementary Note.) As most of these cohorts did not have post-bronchodilator spirometry data, we used modified definitions of GOLD criteria based on pre-bronchodilator spirometry data: forced expiratory volume in 1 s (FEV 1 ) < 80% and FEV 1 to forced vital capacity (FVC) ratio of < 0.7 for cases and FEV 1 > 80% and FEV 1 /FVC > 0.7 for controls. Logistic regression was performed in each cohort, adjusting for age, sex, pack-years of smoking, ever smoking status, current smoking status, and ancestry-based principal components, as appropriate for each study. Summary statistics were assessed using EasyQC 55 version 10.1. More detailed cohort information, including cohort-specific methods, can be found in the Supplementary Note. Genome-wide association quality control. Summary statistics, including effect allele and other allele oriented to the plus strand, effect allele frequency, chromosome and position (hg19), and imputation quality, were uploaded to a secure site at the Brigham and Women's Hospital/Channing Division of Network Medicine. Quality control assessments included assessing allele frequencies versus the 1000 Genomes Project reference, standard error versus sample size, and quantile-quantile plots. Variants with an imputation quality metric of <0.3 (provided a higher threshold for imputation quality was not already implemented) or a minor allele count (MAC) of <20 using the effective sample size or the number of cases and adjusted for imputation quality where applicable were set to missing. Variants were included for meta-analysis if they were present in at least 13 studies (those with European ancestry and at least 7 million markers passing all quality control filters).
Staged GWAS meta-analysis. In stage 1 of the analysis, we used Metal 56 version 2011-03-25 to perform a fixed-effects meta-analysis of genome-wide data from 22 studies and 4 additional COPD cohorts genotyped on an Illumina HumanExome v1.2 platform with custom content; this content included a set of COPD candidate genes and regions identified from previous COPD GWAS efforts 13 . We adjusted for inflation using genomic control correction in each study. We included study populations with subjects of non-European ancestry in the overall analysis and additionally examined results limited to study populations of European ancestry. To identify variants to test for association in stage 2 in the UK BiLEVE study, we selected top results (P < 5 × 10 −6 ) from the stage 1 meta-analysis. We selected one lead variant from the chromosome 15q25, FAM13, and HHIP regions, as all of these have been described in multiple COPD GWAS 13, 16, 17, 21 . For the remainder of the regions, we performed LD pruning using the PLINK1.9 --clump procedure with an r 2 of 0.5, additionally examining these SNPs for the number of cohorts with passing quality control metrics at each variant and including SNPs in strong LD (i.e., part of the same clump) with a lower degree of missingness. To identify independent results, we used GCTA-COJO 57,58 on the stage 1 meta-analysis results for variants with P < 5 × 10 −6 using the default distance of 10 Mb. We used COPDGene non-Hispanic whites (as the largest representative population) as the reference population for these analyses. An overall meta-analysis across the stage 1 and stage 2 (UK BiLEVE) cohorts was performed, and variants with P < 5 × 10 −8 were considered genome-wide significant (Fig. 1). Lung eQTL analysis. Lung eQTLs were calculated from 1,111 human subjects who underwent lung surgery at three academic sites: Laval University, the University of British Columbia, and the University of Groningen, henceforth referred to as Laval, UBC, and Groningen, respectively. This lung eQTL data set has been described previously 22, 59 . Briefly, 66.7-91.2% of the individuals in this study were current or former smokers and 24.2-35.3% had moderateto-severe COPD (GOLD spirometry grade 2 to 4). Whole-genome gene expression profiling in the lung was performed on a custom Affymetrix array (GPL10379). Microarray preprocessing and quality controls were described previously 22, 60, 61 . Probe sequences were mapped to the human genome (hg19) using Bowtie 62 , and probes not mapping to a coding region or having a common SNP (MAF ≥ 5%) in their sequence were removed. Expression data were adjusted for age, sex, and smoking status using residuals obtained with the robust fitting of linear models function (rlm) in the R statistical package MASS. Residual values deviating from the median by more than 3 s.d. were filtered out as outliers. Genotyping was carried out on the Illumina Human 1M-Duo BeadChip array.
Twenty-one of the 22 SNPs in Table 1 were genotyped or imputed in the three cohorts-Laval, UBC, and Groningen. One of the SNPs, rs7186831, was not well imputed; a proxy, rs11865296 in modest LD (r 2 = 0.54, 1000 Genomes Project Phase 3, EUR), was used instead. These variants were tested for association with adjusted expression traits (43,465 probe sets) in the lung. SNPs within 1 Mb up-or downstream of the transcription probe set were considered to be local eQTLs. Distant-acting eQTLs were further than 1 Mb away or on a different chromosome. Association tests were carried out with PLINK1. 9 (refs. 63,64) in each cohort, and meta-analysis was then performed using Fisher's method. All local eQTLs with nominal P < 0.05 in the meta-analysis were considered. To provide an additional overall estimate of eQTL significance, we consid- Colocalization analysis. Colocalization of statistical signals for COPD genetic association and eQTLs was examined using the coloc R package 23 . We used phenotypic summary statistics from individuals of European ancestry with genome-wide association data and all eQTL results and examined 500-kb flanking regions around the top 22 genome-wide significant associations found in the overall meta-analysis ( Table 1) . Sensitivity analysis. To estimate the effect of using pre-bronchodilator instead of post-bronchodilator lung function data on our results, we examined the top set of genome-wide significant results in our largest cohorts with both prebronchodilator and post-bronchodilator data and densely imputed genotypes (COPDGene Non-Hispanic whites and African Americans, ECLIPSE, NETT-NAS, and Norway/GenKOLS). Because subjects from these cohorts (except for COPDGene) were included on the basis of post-bronchodilator values, including all subjects with COPD defined on the basis of post-bronchodilator spirometry data would lead to larger sample sizes and make comparison of P values more difficult. Thus, we chose a random sample of post-bronchodilator cases and controls that matched the number of pre-bronchodilator cases and controls. We performed logistic regression using these equally sized sets of pre-bronchodilator and post-bronchodilator cohorts and carried out meta-analysis on the results.
Asthma overlap analysis.
We assessed the overlap between our results and known asthma susceptibility loci. We downloaded information on genomewide significant (P < 5 × 10 −8 ) associations with asthma and asthma-related traits including asthma and hay fever, asthma (childhood onset), asthma (corticosteroid response), bronchodilator response in asthma, pulmonary function decline, and severe asthma from the NHGRI-EBI GWAS Catalog 42 . Additionally, we examined top associated variants (that were not genome-wide significant) in susceptibility to asthma-COPD overlap syndrome 66 . In total, we assessed association statistics for 49 unique loci for asthma-associated traits across 26 genomic regions in our stage 1 meta-analysis results. We also examined the asthma association statistics of our top COPD loci from the overall meta-analysis using publically available data for asthma GWAS from the GABRIEL Consortium 43 . For COPD loci not present in the GABRIEL Consortium asthma GWAS data, we attempted to examine proxy SNPs in LD (r 2 > 0.5, 1000 Genomes Project Phase 1, CEU) with our top COPD loci.
To examine the genetic correlation 47 of COPD and asthma over the entire genome, we performed LD score regression 46 using summary statistics from publically available data for asthma GWAS from the GABRIEL Consortium 43 . For all comparisons using LD score regression, we filtered to HapMap 3 variants, limited the subjects to European-ancestry subjects with genome-wide data, and filtered on missingness using default parameters in munge_sumstats.py. For the GABRIEL data, we required a variant to be present in at least 35 of the studies.
Smoking behavior overlap analysis. We downloaded information on genomewide significant (P < 5 × 10 −8 ) associations with the traits 'nicotine dependence' and 'smoking behaviour' from the NHGRI-EBI GWAS Catalog 42 . We assessed top smoking-associated SNPs in our stage 1 meta-analysis results. We also assessed overlap of smoking and COPD in publically available summary statistics from the 2010 Tobacco and Genetics Consortium GWAS 45 . We evaluated our top COPD loci from the overall meta-analysis for associations with both cigarettes per day and ever smoking traits. For COPD risk SNPs not directly analyzed in the Tobacco and Genetics Consortium GWAS, we attempted to examine proxy SNPs in LD (r 2 > 0.5, 1000 Genomes Project Phase 1, CEU) with our top COPD loci.
To examine the genetic correlation 47 of COPD and smoking behaviors (cigarettes per day and ever smoking status) over the entire genome, we performed LD score regression 46 using summary statistics from our current COPD study as noted above and publically available summary statistics from the 2010 Tobacco and Genetics Consortium GWAS 45 .
Fine-mapping analysis. We attempted to determine, at each locus, whether we could identify a potentially causal variant. We performed these analyses using European-ancestry subjects alone and in all subjects with genome-wide data, and we excluded variants that were not present in at least 80% of the full sample. We assumed a single causal variant at each locus, examined a 500-kb region centered on the top variant, and calculated approximate Bayes factors using the method of Wakefield 67 to determine the 95% credible set. Although approaches specific for trans-ancestry association mapping 68, 69 can significantly assist in the identification of causal loci, we found that the number of non-European samples in our study was likely insufficient to leverage these methods.
Functional enrichment analysis.
To identify enriched cell types for our COPD associations, we applied LD score regression to GenoSkyline 70 lung tissue annotations (the default LD score regression annotations collapse lung into the cardiovascular tissue type), as well as cell-type-specific annotations from LD score regression 46 . We also performed analysis using only the 22 genome-wide significant loci and tested for enrichment of imputed chromatin marks from Roadmap Epigenomics using HaploReg 4.1 (ref. 29) . Further, we applied a more sophisticated analysis adjusting for local LD patterns, GoShifter 71 . Finally, we examined overlap with gene expression data sets using SNPsea 72 .
Additional pulmonary fibrosis and COPD overlap analysis. To further examine overlapping loci for COPD and pulmonary fibrosis, we combined summary statistics from our study and the pulmonary fibrosis GWAS by Fingerlin et al. 8, 9 using gwas-pw 37 .
Causal gene analysis. For the genome-wide significant loci from the overall meta-analysis, we explored potential causative genes at each association locus using the PrixFixe method 73 , assuming co-function of all significant loci. As required by the PrixFixe method, we ensured our genome-wide significant loci were present in dbSNP v137 and were represented in HapMap 74 phase 3 data; for loci not meeting these requirements, proxy SNPs from HapMap phase 3 were selected on the basis of strongest LD (r 2 ) with the index SNP (see Supplementary Table 11 for details on the proxy variant used at each genome-wide significant locus).
COPD comorbidity overlap analysis. We assessed the overlap between our results and those for two common COPD comorbidities, coronary artery disease and osteoporosis (through bone mineral density traits). We downloaded information on genome-wide significant (P < 5 × 10 −8 ) associations with these comorbidities as reported in the NHGRI-EBI GWAS Catalog 42 . We assessed the association statistics of these comorbid trait loci in our stage 1 metaanalysis results.
Quantitative imaging overlap analysis. To explore the relationship between our top COPD-associated variants and imaging features of emphysema and airway thickness, we queried data from a GWAS of COPD quantitative imaging features 75 . For each genome-wide significant COPD susceptibility locus in our overall meta-analysis, we assessed the corresponding quantitative imaging GWAS effect size, effect direction, and P value for association with the following quantitative imaging traits: %LAA-950 (percentage low attenuation area, using a threshold of -950 Hounsfield units); Perc15 (value of Hounsfield units at the 15th percentile of the density histogram); Pi10 (airway wall area; the value for a hypothetical airway of 10 mm internal perimeter obtained by plotting a regression line of the square root of the airway wall area versus the airway internal perimeter); and WAP (percentage of the wall area as compared to the total bronchial area).
Gene set enrichment analysis. As an attempt to minimize false positives in our gene set enrichment analysis, we divided the stage 1 GWAS cohorts with full genome-wide data into two sets of roughly equal size. We then used i-GSEA4GWAS (http://gsea4gwas.psych.ac.cn/) 76 for each of the two GWAS data sets to assess enrichment of COPD GWAS loci in BioCarta (http://cgap. nci.nih.gov/Pathways/BioCarta_Pathways) and KEGG 77 pathways as well as Gene Ontology (GO) terms 78, 79 . We first evaluated GO terms and pathways with a false discovery rate (FDR) less than 5% in both analysis sets and then used a more stringent threshold of FDR < 1% to evaluate overlap of GO terms and pathway enrichment in our two analysis sets.
Data availability. The genome-wide association summary statistics generated in the stage 1 analysis of the current study are available at the database of Genotypes and Phenotypes (dbGaP) under accession phs000179.v5.p2.
The stage 2 analysis summary statistics are available in Supplementary  Table 3. 
